Indeed, since early 2011, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend EGFR mutation testing for patients with advanced non-squamous NSCLC [7], [8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.